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APPENDIX
The following individuals participated in the conduct
of the trial:
Clinical Sites: Wake Forest University School of
Medicine (Winston-Salem NC): J. Regan, M. Bettmann,
B. Kouri, L. Patella, P. Tesch; Lake Washington Vascular
and Overlake Hospital (Bellevue, Wash): K. Gibson,
B. Ferris, D. Pepper, T. Fortney, A. Ebert, C. Leafdale,
H. Covert; University of Southern CaliforniaMedical Cen-
ter (Los Angeles, Calif): V. Rowe, F. Weaver, D. Hood,
C. Pappas, S. Parese; Duke University School of Medicine
(Durham, NC): C. Shortell, T. Williams, S. Finley; Univer-
sity of Pittsburgh-Shadyside (Pittsburgh, Pa): S. Hirsch,
E. Dillavou, J. Brimmeier, T. Richardson.
Data and Safety Monitoring Board: Carlos Kase,
MD (chair) and Ravin Davidoff, MD (Boston Medical
Center), Howard Rowley, MD (University of Wisconsin-
Madison), Mark Espeland, PhD (Wake Forest University
School of Medicine).
Study Proctors: Mark Isaacs, MD, John Mauriello,
MD, David Wright, MB, FRCS.
Transcranial Doppler Core Laboratory (Sentient
Neurocare Services, Inc.): Alex Razumovsky, PhD (inde-
pendent reviewer), David Pilchard.
MRI Independent Review: Lyle R. Gesner, MD.
Perceptive Informatics: James Paskevitz, MD, Mat-
thew Hayden.
Parexel Clinical Services: E. Carter, E. Leip, S. Zand-
man, T. Zuttermeister.
BTG International: D.Wright, J. Rush, G. Suplick, J.Barclay, K. Arcuri, E. Evans, C. Tedesco, P. Mussenden.INVITED COMMENTARYPeter Gloviczki, MD, Rochester, Minn
During the past decade, foam sclerotherapy has been widely
used around the world for treatment of varicose veins, for ablation
of the incompetent saphenous veins, for perforating veins, or for
treatment of venous malformations. Although liquid forms of the
two most frequently used sclerosing agents, sotradecol and poli-
docanol, are now approved by the Federal Drug Administration
(FDA), the use of foam has no FDA approval in the United States.
Two European consensus meetings concluded that foam sclero-
therapy was a safe, effective, and minimally invasive treatment of
varicose veins with a low rate of complications.1,2
Reported complications of foam sclerotherapy have been in-
deed rare.3 In a prospective multicenter study, Guex et al4 reportedwith foam. Forty-nine incidents (0.4%) occurred, 37 after admin-
istration of foam. There were 20 cases of transient visual distur-
bances; in 19 cases, foam or air block was used. One patient
developed femoral vein thrombosis. In a systematic review of data
of more than 9000 patients who underwent foam sclerotherapy,
the rate of serious adverse effects, including pulmonary embolism
and deep vein thrombosis, was less than 1%. The median rate of
visual disturbance was 1.4%, headache occurred in 4.2%, and
thrombophlebitis in 4.7%.
Concerns about the use of foam have been raised when Bush5
and other authors6,7 reported on cases of stroke after foam sclero-
therapy in patients who had a patent foramen ovale. Factors
believed to increase the risk of stroke included the use of air instead
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during one session, large bubble size, failure to elevate the limb
after treatment, and prolonged immobility.6,8,9 Standardization of
the bubble size using commercially prepared microfoam10 and the
replacement of air with CO2 in the solution have been suggested to
decrease the risk of neurologic complications.11
In a prospective, uncontrolled study published in this issue of
the Journal of Vascular Surgery, Regan at al performed ablation of
the great saphenous vein in 82 patients with chronic venous
insufficiency using ultra-low nitrogen polidocanol microfoam.
Sixty patients with evidence of microemboli in the middle cerebral
artery were evaluated for microinfarction in the brain using mag-
netic resonance imaging (MRI) and for myocardial infraction
measuring cardiac troponin-I. Eighty-one patients were followed
for 28 days; duplex scanning confirmed occlusion of the saphenous
vein in 88%. Only one patient (1.2%) had a transient (20 seconds
long) visual disturbance, and none developed cerebral microem-
boli, myocardial infarction, or clinically significant pulmonary em-
bolism.
While this study demonstrated that microfoam treatment of
the saphenous vein in 60 patients with right-to-left shunt did not
cause cerebral infarction, the lack of a control group of patients
with bedside preparation of the foam clearly weakens the value of
the information. Even with a control group, the study would have
a high chance for Type II error since many more patients are
needed to show any difference in the risk of complications. The
number of patients would depend on the rate of subclinical micro-
emboli, detected by the authors’ technique in patients treated with
foam prepared from an air-sclerosing solution mixture: a study that
alone is needed to give us valuable information on the risk of using
room air in foam for sclerotherapy.
The 10% risk of failed treatment by 28 days and other side-
effects reported in this study are disconcerting. Adverse events
included pain or discomfort in the treated limb in 45%, deep vein
thrombosis occurred in 7.4%, and secondary procedures to express
thrombus from the treated saphenous vein were needed in 13.5%.
These complications are higher than what was reported in any
previous study with foam, and further refinement of the technique
presented here is clearly warranted.
There is a great need for minimally invasive treatment of
millions of people with chronic venous disease. Endovenous ther-
mal ablation with radiofrequency or laser has been a major step in
the right direction to replace the traditional high ligation and
stripping in many patients. Foam is also here to stay for treatment
of varicose veins;12,13 therefore, the authors’ efforts to produce a
safe product and a minimally invasive technique for venous abla-
tion should be applauded. This prospective trial by Regan and
colleagues was an important step in the right direction. However,
further controlled clinical trials with a much larger number ofpatients are needed to answer two important questions on foam
sclerotherapy: is ultra-low nitrogen polidocanol microfoam supe-
rior to room-air microfoam, and will ultra-low-nitrogen polidoca-
nol microfoam prevent neurologic complications?
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